Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer

BACKGROUND: Molecular imaging with novel radiotracers is changing the treatment landscape in prostate cancer (PCa). Currently, standard of care includes either conventional and molecular imaging at time of biochemical recurrence (BCR). This study evaluated the determinants of and cost associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Borno, Hala T., Kuo Lin, Tracy, Odisho, Anobel Y., Desai, Arpita, Koshkin, Vadim, Werner, Kalin, Legaspi, Nichole, Bucknor, Matthew, Bell, Alexander, Zhang, Sylvia, Hope, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826487/
https://www.ncbi.nlm.nih.gov/pubmed/33247633
http://dx.doi.org/10.1002/cam4.3555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826487/
https://www.ncbi.nlm.nih.gov/pubmed/33247633
http://dx.doi.org/10.1002/cam4.3555

Ejemplares similares